Your session is about to expire
← Back to Search
Local Anesthetic
Lidocaine + epinephrine vs Ropivacaine for Local Anesthesia
Phase 4
Waitlist Available
Led By Kira Minkis, MD, PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 hours.
Awards & highlights
Study Summary
This trial compares the effectiveness of short and long-acting injectable pain treatments commonly used in skin surgery. Researchers will compare the duration of action of two long-acting anesthetics.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 hours.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 hours.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time to Return to Baseline Sensation, as determined by binary outcomes (yes/no) in 15 minute increments
Trial Design
3Treatment groups
Experimental Treatment
Group I: Ropivacaine vs BupivacaineExperimental Treatment2 Interventions
Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of Naropin (ropivacaine) 0.5% into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
Group II: Lidocaine + epinephrine vs RopivacaineExperimental Treatment2 Interventions
Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of . Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 0.5ml of Naropin (ropivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
Group III: Lidocaine + epinephrine vs BupivacaineExperimental Treatment2 Interventions
Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of lidocaine + epinephrine into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
lidocaine + epinephrine 1:100,000
2023
Completed Phase 4
~80
Ropivacaine 0.5% Injectable Solution
2021
Completed Phase 4
~1310
Bupivacaine 0.5% Injectable Solution
2023
Completed Phase 4
~80
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,059 Previous Clinical Trials
1,317,030 Total Patients Enrolled
Kira Minkis, MD, PhDPrincipal InvestigatorWeill Medical College of Cornell University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this medical experimentation currently enlisting participants?
"Clinicaltrials.gov states that this trial, initially created on March 1st 2023 and revised recently on the 2nd of the same month, is currently not enrolling patients. However, 12 other trials are still looking for volunteers."
Answered by AI
How does the safety of Lidocaine + epinephrine compare to that of Ropivacaine for patients?
"Our team at Power gave the safety of Lidocaine + epinephrine vs Ropivacaine a score of 3, which reflects its approved status as it is in Phase 4 trials."
Answered by AI
Share this study with friends
Copy Link
Messenger